Retention Rates of Biological Drugs in Spondyloarthritis: A 24-Month Observational Study in Patients Aged 60 Years or Older.

ABSTRACT:

Background

Older adults are under-represented in clinical trials investigating spondyloarthritis (SpA), limiting the generalizability of efficacy and safety data for this population. In this context, real-world evidence on drug retention and treatment discontinuation is essential to guide long-term therapeutic decisions, particularly for biologic disease-modifying antirheumatic drugs (bDMARDs) and apremilast.

Objectives

This study aimed to assess the 24-month retention rates of bDMARDs and apremilast in patients aged ≥ 60 years with SpA.

Methods

This was a single-center, observational study conducted over 24 months at Azienda Ospedaliero-Universitaria Policlinico "Gaspare Rodolico - San Marco" Catania. Patients aged ≥ 60 years with SpA, classified according to the Ass

SUBMITTER: Foti R 

PROVIDER: S-EPMC12634917 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature